← back to search

Lunxu Liu

University of Hong Kong · CN
Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Pleural and Pulmonary Diseases, and Tracheal and airway disorders.
h-index
50
citations
10,157
works
516
NIH funding
primary concept
Medicine
email

Recent publications

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
Journal of Clinical Oncology 2025cited by 49position: middledoi
Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer
Nature Communications 2025cited by 29position: middledoi
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
Signal Transduction and Targeted Therapy 2025cited by 5position: middledoi
A multiomics dataset of paired CT image and plasma cell-free DNA end motif for patients with pulmonary nodules
Scientific Data 2025cited by 3position: middledoi
Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)
Cancer Research 2025cited by 3position: middledoi
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
JAMA 2024cited by 316position: middledoi
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
The Lancet Respiratory Medicine 2024cited by 98position: middledoi
Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target
Genome Medicine 2024cited by 33position: middledoi
Ligand recognition and G-protein coupling of trace amine receptor TAAR1
Nature 2023cited by 66position: middledoi
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma
Molecular Cancer 2022cited by 44position: middledoi
Expert consensus on resection of chest wall tumors and chest wall reconstruction
Translational Lung Cancer Research 2021cited by 79position: middledoi
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Nature Communications 2021cited by 73position: middledoi
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Translational Lung Cancer Research 2021cited by 22position: middledoi
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Journal of Clinical Oncology 2020cited by 275position: middledoi
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Translational Lung Cancer Research 2020cited by 54position: lastdoi
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Lung Cancer 2020cited by 9position: middledoi
Albumin-to-alkaline phosphatase ratio as a novel prognostic indicator for patients undergoing minimally invasive lung cancer surgery: Propensity score matching analysis using a prospective database
International Journal of Surgery 2019cited by 51position: lastdoi
International expert consensus on the management of bleeding during VATS lung surgery
Annals of Translational Medicine 2019cited by 42position: firstdoi
Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery
Translational Lung Cancer Research 2019cited by 39position: middledoi
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Translational Lung Cancer Research 2019cited by 31position: middledoi
Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma
2019cited by 0position: middle
MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression
Cell Death and Disease 2018cited by 93position: middledoi
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Journal of Thoracic Oncology 2018cited by 72position: middledoi
Pin1 impairs microRNA biogenesis by mediating conformation change of XPO5 in hepatocellular carcinoma
Cell Death and Differentiation 2018cited by 52position: middledoi
The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer
Journal of Thoracic Disease 2018cited by 27position: middledoi
Society for Translational Medicine Expert Consensus on the preoperative assessment of circulatory and cardiac functions and criteria for the assessment of risk factors in patients with lung cancer
Journal of Thoracic Disease 2018cited by 13position: middledoi
Society for Translational Medicine expert consensus on training and certification standards for surgeons and assistants in minimally invasive surgery for lung cancer
Journal of Thoracic Disease 2018cited by 4position: firstdoi
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
The Lancet Oncology 2017cited by 527position: middledoi
The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy
Journal of Thoracic Disease 2017cited by 58position: middledoi
The Society for Translational Medicine: clinical practice guidelines for mechanical ventilation management for patients undergoing lobectomy
Journal of Thoracic Disease 2017cited by 26position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Bentong Yu · Nanchang University3 papers (2024–2025)Jiajun Deng · First Affiliated Hospital of Jinan University2 papers (2025–2025)Yong Peng · People's Hospital of Shiyan2 papers (2018–2018)Qun Wang · Liaoning University2 papers (2013–2013)Jun Zhang · Hebei Agricultural University2 papers (2025–2025)Tingting Wang · Sun Yat-sen University2 papers (2025–2025)Chang Chen · The First People's Hospital of Shunde2 papers (2025–2025) · 2 papers (2025–2025)Jianxing He · First Affiliated Hospital of Guangzhou Medical University2 papers (2013–2013)Yongxiang Song · Tianjin University2 papers (2025–2025)Xinlei Hu · China Pharmaceutical University2 papers (2025–2025)Mengmeng Zhao · Tulane University2 papers (2025–2025)Guofang Zhao · Ningbo University2 papers (2025–2025)Gang Xue · Sinopec (China)2 papers (2025–2025)Jiankang Zhou · Sichuan University2 papers (2018–2018) · 2 papers (2025–2025) · 2 papers (2025–2025)Yiming He · Tongji University2 papers (2025–2025)Gening Jiang · Shanghai University2 papers (2013–2013)Deping Zhao · Second Military Medical University2 papers (2025–2025)